Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. (AMST) reported first‑quarter results for the period ended September 30, 2025. Revenue was $94,296, up from $11,250 a year ago, as the company shifted focus toward healthcare with its NurseMagic product. Mix included B2B $70,244 (74%) and B2C $24,052 (26%). Operating discipline reduced expenses: G&A $547,060 (vs. $633,122), technology and content $102,888 (vs. $139,658), and sales and marketing $106,472 (vs. $165,814).
The company posted a net loss of $642,266 (vs. $908,045), with operating cash outflow of $415,765. Cash, cash equivalents, and restricted cash totaled $1,930,053 at quarter‑end, including a short‑term U.S. Treasury fund of approximately $1.65 million with 7‑day liquidity. Deferred revenue was $24,655. One customer represented 12% of revenue.
Management disclosed conditions that raise substantial doubt about Amesite’s ability to continue as a going concern. Plans contemplate financing transactions, which are subject to market conditions. Shares outstanding were 4,572,713 as of October 24, 2025.
Amesite Inc. (AMST) reported a Section 16 filing showing that on 09/30/2025 the reporting person received 3,934 restricted stock units (RSUs) as deferred compensation for board service. Each RSU represents a contingent right to one share of common stock or a cash equivalent calculated using the closing price on the quarter end. The RSUs were issued in lieu of cash director fees and will be delivered upon completion of board service or earlier upon a change in control. After the transaction, the reporting person beneficially owns 61,912 shares indirectly through the Gilbert S. Omenn Revocable Trust. The Form 4 was executed by an attorney-in-fact on 10/02/2025.
George Parmer, a director of Amesite Inc. (AMST), was issued 3,934 restricted stock units (RSUs) on 09/30/2025 as deferred compensation in lieu of cash. Each RSU represents a contingent right to one share of AMST common stock or a cash equivalent, and the number of units was calculated using the closing share price on the last day of the quarter. The RSUs are payable upon completion of Mr. Parmer's board service or, if earlier, a change in control. Following this grant, Mr. Parmer beneficially owns 55,016 shares of AMST common stock. The units were reported with an indicated price of $0 because they represent deferred compensation, not a cash purchase.
Amesite Inc. (AMST) director J. Michael Losh was granted 4,754 restricted stock units (RSUs) on 09/30/2025 as deferred compensation in lieu of cash. Each RSU represents a contingent right to one share of AMST common stock or the cash equivalent. The RSUs were calculated using the closing share price on the last day of the quarter and will be delivered upon completion of board service or earlier upon a change in control. After this transaction, the reporting person beneficially owns 74,811 shares of common stock indirectly through the J. Michael Losh Irrevocable Qualified Annuity Trust #7. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Losh and filed on 10/02/2025.
Amesite Inc. (AMST) reported a net loss of approximately $3,617,000 for the fiscal year ended June 30, 2025 and had stockholders' equity of about $2,739,000 on that date. The company had 4,572,713 shares outstanding at June 30, 2025 versus 2,542,440 a year earlier, reflecting recent equity issuances. Amesite completed a public offering of 1,201,667 shares at $3.00 per share, generating approximately $3.6 million gross and about $3.1 million net proceeds, with direct offering costs of $1,164,050 deducted from equity.
The company recorded a $90,869 impairment of capitalized software after discontinuing a higher ed/professional learning app to focus on its NurseMagic app, and recognized warrants issued in connection with underwriting with a fair value of approximately $95,984. Revenues show customer concentration: one line notes 41% of revenues from a single source and that five customers accounted for 97% of 2024 revenue. Cash, cash equivalents and restricted cash of about $2,433,000 are reported.
Amesite (Nasdaq: AMST) filed an 8-K on June 26 2025 announcing a change in its independent auditor.
The Audit Committee dismissed Turner, Stone & Company, whose FY 2024 report contained a going-concern paragraph, and appointed Novogradac & Company effective June 24 2025.
- No disagreements with the former auditor were reported.
- Previously disclosed material weaknesses in internal controls over journal entries, stock-based compensation and deferred revenue remain a reportable event.
- Turner Stone’s concurrence letter is filed as Exhibit 16.1.
The auditor switch may influence audit timelines, remediation efforts and investor perception of financial reporting quality.